Clearmind Medicine
CMND
1 hedge funds and large institutions have $12K invested in Clearmind Medicine in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
6.59% less ownership
Funds ownership: 6.59% → 0% (-6.6%)
75% less funds holding
Funds holding: 4 → 1 (-3)
96% less capital invested
Capital invested by funds: $288K → $12K (-$276K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$29K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.9K |
| 3 |
Morgan Stanley
New York
|
-$2.63K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$404 |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$387 |
CMND Hedge Fund Activity: Q4 2025 in Review
1 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q4 2025, worth a combined $12K — down 96% from $288K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CMND and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was AdvisorShares Investments, adding an estimated $20.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $29K sold.
- 1 institutional investor held Clearmind Medicine (CMND) as of Q4 2025, down from 4 in Q3 2025.
- Funds reported $12K of Clearmind Medicine stock for Q4 2025, down 96% quarter-over-quarter.
- 0 funds opened new Clearmind Medicine positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Clearmind Medicine buyer in Q4 2025 was AdvisorShares Investments, an estimated $20.7K added.
- The largest Clearmind Medicine seller in Q4 2025 was Virtu Financial, an estimated $29K sold.
Based on aggregated 13F filings for Q4 2025.